MYC_pLX307 Citations (4)

Originally described in: Genetic and Proteomic Interrogation of Lower Confidence Candidate Genes Reveals Signaling Networks in beta-Catenin-Active Cancers.
Rosenbluh J, Mercer J, Shrestha Y, Oliver R, Tamayo P, Doench JG, Tirosh I, Piccioni F, Hartenian E, Horn H, Fagbami L, Root DE, Jaffe J, Lage K, Boehm JS, Hahn WC Cell Syst. 2016 Sep 28;3(3):302-316.e4. doi: 10.1016/j.cels.2016.09.001. PubMed Journal

---

Articles Citing MYC_pLX307

Articles
Heart failure drug proscillaridin A targets MYC overexpressing leukemia through global loss of lysine acetylation. Da Costa EM, Armaos G, McInnes G, Beaudry A, Moquin-Beaudry G, Bertrand-Lehouillier V, Caron M, Richer C, St-Onge P, Johnson JR, Krogan N, Sai Y, Downey M, Rafei M, Boileau M, Eppert K, Flores-Diaz E, Haman A, Hoang T, Sinnett D, Beausejour C, McGraw S, Raynal NJ. J Exp Clin Cancer Res. 2019 Jun 13;38(1):251. doi: 10.1186/s13046-019-1242-8. PubMed
Mistletoe lectin inhibits growth of Myc-amplified small-cell lung cancer. Shatat MA, Gauthier B, Yoon S, Yuan E, Yang P, Narla G, Dowlati A, Lee RT. Cancer Med. 2022 Dec 23. doi: 10.1002/cam4.5558. PubMed
Genomic screening reveals ubiquitin-like modifier activating enzyme 1 as a potent and druggable target in c-MYC-high triple negative breast cancer models. Jacob S, Turner TH, Cai J, Floros KV, Yu AK, Coon CM, Khatri R, Alzubi MA, Jakubik CT, Bouck YM, Puchalapalli M, Shende M, Dozmorov MG, Boikos SA, Hu B, Harrell JC, Benes CH, Koblinski JE, Costa C, Faber AC. PNAS Nexus. 2022 Oct 11;1(5):pgac232. doi: 10.1093/pnasnexus/pgac232. eCollection 2022 Nov. PubMed
Synergy between BRD9- and IKZF3-Targeting as a Therapeutic Strategy for Multiple Myeloma. Chowdhury B, Garg S, Ni W, Sattler M, Sanchez D, Meng C, Akatsu T, Stone R, Forrester W, Harrington E, Buhrlage SJ, Griffin JD, Weisberg E. Cancers (Basel). 2024 Mar 28;16(7):1319. doi: 10.3390/cancers16071319. PubMed

If you have published an article using this material, please email us at to have your article added to this page.